Recent News
Powered by Alpha Vantage
No recent news found.
AI Tools
Key Metrics
Trend: Downtrend
Source: Snapshot
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, is engaged in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. The company is headquartered in Ramat Gan, Israel.
52W High
$2.70
52W Low
$0.86
MA Status:
50D: Below
200D: Below
Beta (~1 neutral, <0.9 lower risk)
0.96
Valuation
As of 2025-03-31 (Overview)
Trailing P/E (<15 better)
N/A
Forward P/E (<15 better)
N/A
EV/EBITDA (<8 favorable)
16.88
EV/Revenue (<3 favorable)
21.52
P/S (TTM) (<3 favorable)
25.01
P/B (<3 favorable)
2.02
Ownership
Retail‑heavySource: Overview
Insiders (1–5% typical)
41.29%
Institutions (25–75% balanced)
2.69%
Shares Outstanding
8,813,800
Float
451,886,000
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-03-31 (Overview)
Revenue (TTM)
451,000
Gross Profit (TTM)
3,000
EPS (TTM)
-0.30
Profit Margin (>10% good)
-2.28%
Operating Margin (TTM) (higher better)
-2.01%
ROE (TTM) (>15% strong)
-0.27%
EPS YoY (Quarterly) (>10% good)
-0.76
Revenue YoY (Quarterly) (>8% good)
N/A
Momentum
Bearish momentumValue
-0.0094
Previous
-0.0142
Trend
Rising
Signal Cross
No cross
As of
Sep. 12, 2025